![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PKHD1L1 |
Gene summary for PKHD1L1 |
![]() |
Gene information | Species | Human | Gene symbol | PKHD1L1 | Gene ID | 93035 |
Gene name | PKHD1 like 1 | |
Gene Alias | PKHDL1 | |
Cytomap | 8q23.1-q23.2 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q86WI1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
93035 | PKHD1L1 | AEH-subject1 | Human | Endometrium | AEH | 6.64e-04 | 3.40e-01 | -0.3059 |
93035 | PKHD1L1 | AEH-subject2 | Human | Endometrium | AEH | 2.79e-11 | 5.40e-01 | -0.2525 |
93035 | PKHD1L1 | AEH-subject3 | Human | Endometrium | AEH | 1.67e-37 | 9.11e-01 | -0.2576 |
93035 | PKHD1L1 | AEH-subject4 | Human | Endometrium | AEH | 4.30e-22 | 7.97e-01 | -0.2657 |
93035 | PKHD1L1 | AEH-subject5 | Human | Endometrium | AEH | 3.99e-91 | 1.48e+00 | -0.2953 |
93035 | PKHD1L1 | EEC-subject1 | Human | Endometrium | EEC | 1.49e-31 | 8.25e-01 | -0.2682 |
93035 | PKHD1L1 | EEC-subject2 | Human | Endometrium | EEC | 3.28e-09 | 4.13e-01 | -0.2607 |
93035 | PKHD1L1 | EEC-subject4 | Human | Endometrium | EEC | 1.50e-70 | 1.43e+00 | -0.2571 |
93035 | PKHD1L1 | EEC-subject5 | Human | Endometrium | EEC | 4.22e-07 | 3.50e-01 | -0.249 |
93035 | PKHD1L1 | male-WTA | Human | Thyroid | PTC | 3.66e-10 | 1.47e-01 | 0.1037 |
93035 | PKHD1L1 | nodule-WTA | Human | Thyroid | goiters | 6.71e-04 | 3.55e-01 | 0.0534 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PKHD1L1 | SNV | Missense_Mutation | c.8044G>A | p.Gly2682Arg | p.G2682R | Q86WI1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PKHD1L1 | SNV | Missense_Mutation | c.8045G>T | p.Gly2682Val | p.G2682V | Q86WI1 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PKHD1L1 | SNV | Missense_Mutation | novel | c.5327N>G | p.Leu1776Trp | p.L1776W | Q86WI1 | protein_coding | deleterious(0.02) | probably_damaging(0.982) | TCGA-86-8279-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR |
PKHD1L1 | SNV | Missense_Mutation | c.6013N>T | p.Asn2005Tyr | p.N2005Y | Q86WI1 | protein_coding | tolerated(0.9) | benign(0) | TCGA-91-6831-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PKHD1L1 | SNV | Missense_Mutation | rs758332120 | c.11509N>A | p.Pro3837Thr | p.P3837T | Q86WI1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-91-8499-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PKHD1L1 | SNV | Missense_Mutation | c.5089N>T | p.His1697Tyr | p.H1697Y | Q86WI1 | protein_coding | tolerated(0.27) | benign(0.047) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
PKHD1L1 | SNV | Missense_Mutation | novel | c.3491C>A | p.Ser1164Tyr | p.S1164Y | Q86WI1 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-95-7562-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
PKHD1L1 | SNV | Missense_Mutation | novel | c.5491C>A | p.Pro1831Thr | p.P1831T | Q86WI1 | protein_coding | tolerated(0.13) | possibly_damaging(0.855) | TCGA-95-7562-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
PKHD1L1 | SNV | Missense_Mutation | c.5492C>G | p.Pro1831Arg | p.P1831R | Q86WI1 | protein_coding | tolerated(0.13) | probably_damaging(0.969) | TCGA-95-7562-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD | |
PKHD1L1 | SNV | Missense_Mutation | c.5333A>G | p.Asp1778Gly | p.D1778G | Q86WI1 | protein_coding | tolerated(0.11) | benign(0.013) | TCGA-97-7547-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | vinorelbine | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |